Recent advances in the treatment of erectile dysfunction

Mobley, David F.; Khera, Mohit; Baum, Neil

doi:10.1136/postgradmedj-2016-134073

Cited by 124 publications

(106 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pathophysiology of ED in diabetes is multifactorial, consisting of both vascular, hormonal, and neurologic insults [175]. There are a number of therapeutic options for management of ED including phosphodiesterase type 5 (PDE5) inhibitors which remain the mainstay of initial therapy [178]. Avanafil, sildenafil, tadalafil, and vardenafil are all proven to be safe and effective for managing ED [179][180][181][182][183][184][185].…”

Section: Erectile Dysfunction (Ed)mentioning

confidence: 99%

“…Avanafil, sildenafil, tadalafil, and vardenafil are all proven to be safe and effective for managing ED [179][180][181][182][183][184][185]. Additional treatments include testosterone replacement therapy, intracavernosal injection therapy, vacuum constriction devices (VCDs), intraurethral prostaglandin suppositories and surgical placement of a penile prosthesis [178]. Multifactorial therapy is warranted in more complex cases which may include psychological intervention [178].…”

Section: Erectile Dysfunction (Ed)mentioning

confidence: 99%

See 1 more Smart Citation

State-of-the-art pharmacotherapy for diabetic neuropathy

Azmi

Alam

Burgess

et al. 2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction: The global epidemic of diabetes has led to an epidemic of diabetes complications. Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting ~50% of patients. DPN results in pain with a poor quality of life and a loss of sensation with an increased risk of foot ulceration. Autonomic neuropathy can cause significant morbidity in a minority and is associated with increased mortality. The cornerstone of treatment to prevent or limit the progression of DPN/AN is multifactorial risk factor modification including treatment of glycemia, lipids and blood pressure. Whilst, there are no FDA-approved disease-modifying therapies, there are a number of therapies to relieve symptoms in DPN and AN. Areas covered: The authors discuss current approved therapies for painful diabetic neuropathy and autonomic neuropathy. They also address the potential role of improving risk factors to limit the development and progression of diabetic neuropathy and new pathogenetic and pain-relieving treatments. Expert opinion: The FDA-approved Pregabalin and Duloxetine over 25 years ago and Tapentadol, 6 years ago for painful diabetic neuropathy. There are currently no FDA-approved disease-modifying treatments for diabetic neuropathy which has been attributed to inappropriate models of the disease with limited translational capacity and major limitations of trial designs and endpoints in clinical trials.

show abstract

Section: Erectile Dysfunction (Ed)mentioning

confidence: 99%

Section: Erectile Dysfunction (Ed)mentioning

confidence: 99%

State-of-the-art pharmacotherapy for diabetic neuropathy

Azmi

Alam

Burgess

et al. 2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…It can be cured by various treatments. There are recent advances in the sciences which help in coping up with the disease [81]. Treatment can be done by drugs and changes in the life style and daily routine habits [81].…”

Section: Sexual Dysfunctionmentioning

confidence: 99%

“…There are recent advances in the sciences which help in coping up with the disease [81]. Treatment can be done by drugs and changes in the life style and daily routine habits [81]. Various oral therapies available in the treatment of the ED include sildenafil citrate, tadalafil and vardenafil (Levitra) etc.…”

Section: Sexual Dysfunctionmentioning

confidence: 99%

Pathophysiological Ramifications of Diabetic Condition: A Review

Shahi¹,

Vss²,

Imam³

et al. 2018

Asian J Biomed Pharmaceut Sci

View full text Add to dashboard Cite

Diabetes is a chronic hyperglycaemic disorder. Due to altered metabolism of insulin and related pathways, consistently raised blood glucose levels leads to manifestation of collateral pathophysiologies or complications. Such long term complications include cardiovascular diseases, nephropathy, neuropathy and retinopathy. Microvascular complications are the major cause of these pathologies. Understanding the etiology of these complications is important to devise effective prevention and treatment strategies. Therefore, the current review was undertaken to enumerate various diabetes related pathologies, the relevant mechanisms, disease progression and available treatment options. The data was collected from major indexing services like-PubMed, Scopus, Google Scholar and some related journals which fall under the scope of the review paper. The major keywords which were used for the collection of data include diabetes, pathophysiology of diabetes, comorbidities of diabetes, diabetes complications, diabetes management, diagnosis of diabetes, diagnosis of comorbidities of diabetes etc. Most of the articles referred are published in last 8 years. However, some relevant articles are also considered which are published before this time frame.

show abstract

“…The recognition that phosphodiesterase inhibitors could improve erectile dysfunction was made in 1998 (13) and sildenafil and other agents became available ten years later (14,15). Other treatments for erectile dysfunction such as penile prostheses, penile injections and vacuum tumescence devices also became available (16)(17)(18). When physicians neglect to take sexual histories and discuss sexual health issues with their patients, they are also less likely to be treating changes in sexual functioning.…”

mentioning

confidence: 99%